Most Read Articles
14 Jan 2016
Tocotrienols are one of the two classes of compounds generally known as vitamin E. Prominent researcher in pharmaceutical technology, Professor Yuen Kah Hay, recently spoke to MIMS Doctor about the neuroprotective benefits conferred by palm tocotrienols. He shared key insights from a clinical trial performed by his team and about the compound’s potential for clinical use.
19 Feb 2017
There appears to be no association between Toxoplasma gondii and Parkinson’s disease, although exposure to T. gondii may have an effect on specific types of Parkinson’s disease, according to a recent study.
Dr. Angela V. Ignacio, 23 Feb 2017
The use of mirror therapy appears to be effective in treating left visual hemineglect in stroke patients and may be combined with transcutaneous electrical nerve stimulation (TENS) for rehabilitation management in this population, according to a study presented at the 7th Association of South-East Asian Pain Societies Congress (ASEAPS 2017) held in Yangon, Myanmar.

ADD, NF1 clinically similar but neurophysiologically different

19 Mar 2017
Growth charting methods may be used to identify presence of ADHD

Despite their considerable similarities in terms of clinical features, attention deficit disorder (ADD) and neurofibromatosis type 1 (NF1) have important neurophysiological differences, particularly in perceptual categorization and response inhibition, a new study shows.

The study included 29 patients with either NF1 (n=13) or ADD (n=16). Only those diagnosed according to the NIH and ICD criteria were included. Of the ADD patients, six were taking methylphenidate or atomoxetine medication. An additional 17 children without psychiatric conditions were included as controls.

Participants underwent a standard Go/No-go task requiring them to respond adequately to a “press” or “stop” stimulus. Electroencephalogram (EEG) readings during the onset of the stimuli were recorded. Only those for correct responses were considered.

ADD patients (51.8±15.8 percent) had more false alarm response in the No-go tests compared with controls (31.8±16.5 percent; p=0.003) and patients with NF1 (34.8±19.8 percent; p=0.03). The difference between the NF1 patients and the controls was insignificant (p=0.64).

There was a significant difference among the three groups in terms of the correct responses in the Go tests (ADD: 92.9±7.8 percent; NF1: 90.9±10.3 percent; controls: 97.9±2.7 percent; p=0.03). Moreover, the difference between the NF1 patients and the controls were significant (p=0.01).

The NF1 patients (491±135 ms) also had significantly slower reaction times in the Go tests compared with ADD patients (415±55 ms; p=0.02) and controls (416±98 ms; p=0.02).

Neurophysiological data showed that NF1 patients had lower P1 amplitudes compared with ADD patients (p=0.01) and controls (p=0.02). The difference between controls and ADD patients was insignificant (p=0.66).

ADD patients had a lower central P3 (cP3) peak compared with controls (p=0.001) and NF1 patients (p=0.02) in the No-go tests. On the other hand, NF1 patients showed a significantly later cP3 peak compared with ADD patients (p=0.007) and controls (p=0.05) in the No-go tests.

The differences highlighted in the study show that both clinical and cognitive-neurophysiological measures are important in assessing these disorders.

Editor's Recommendations
Most Read Articles
14 Jan 2016
Tocotrienols are one of the two classes of compounds generally known as vitamin E. Prominent researcher in pharmaceutical technology, Professor Yuen Kah Hay, recently spoke to MIMS Doctor about the neuroprotective benefits conferred by palm tocotrienols. He shared key insights from a clinical trial performed by his team and about the compound’s potential for clinical use.
19 Feb 2017
There appears to be no association between Toxoplasma gondii and Parkinson’s disease, although exposure to T. gondii may have an effect on specific types of Parkinson’s disease, according to a recent study.
Dr. Angela V. Ignacio, 23 Feb 2017
The use of mirror therapy appears to be effective in treating left visual hemineglect in stroke patients and may be combined with transcutaneous electrical nerve stimulation (TENS) for rehabilitation management in this population, according to a study presented at the 7th Association of South-East Asian Pain Societies Congress (ASEAPS 2017) held in Yangon, Myanmar.